Non-Pneumatic Compression Devices Offer Fresh Hope for Lymphedema and Venous Disease Patients
A new generation of non-pneumatic compression devices (NPCDs) is emerging as a safe, effective, and user-friendly alternative to traditional pneumatic compression devices (PCDs) for the treatment of lymphedema, phlebolymphedema, venous insufficiency, lipedema, and chronic edema-related conditions. Endorsed by both the American Venous Forum (AVF) and the American Vein and Lymphatic Society (AVLS), these devices represent a therapeutically advanced hybrid approach to edema management.
What are Non-Pneumatic Compression Devices?
The Dayspring (Koya Medical) mobile, non-pneumatic compression device was initially cleared by the US Food and Drug Administration (FDA) in 2021 as a prescription-only treatment. Unlike traditional PCDs, NPCDs don’t rely on stationary air compressors or air-inflated sleeves. Instead, they utilize a compact, mobile-powered controller and limb-specific garments to deliver programmable, sequential gradient compression.
Clinical Evidence Supporting NPCDs
NPCDs have been used to treat over 10,000 patients and have been evaluated in 11 research studies. Research led by former AVF president Glenn Jacobowitz and colleagues demonstrates the safety, efficacy, and clinical superiority of NPCDs compared to standard advanced pneumatic compression.
TEAYS Study Results
A randomized, crossover head-to-head study, TEAYS (Treatment effectiveness of a non-pneumatic compression device versus an advanced pneumatic compression device for lower extremity lymphoedema swelling), published in 2024 in the Journal of Vascular Surgery: Venous and Lymphatic Disorders (JVS-VL), showed significant benefits for patients using NPCDs:
- Limb Volume Reduction: Patients using NPCDs experienced a mean limb volume reduction of 369.9mL, significantly greater than the 83.1mL reduction observed with advanced PCDs.
- Quality of Life: NPCD users reported significant improvements in overall Lymphedema Quality of Life Questionnaire (LYMQOL) scores, with a mean improvement of 1.01 compared to 0.17 for advanced PCD users.
- Adherence: NPCD users demonstrated an 81% adherence rate, significantly higher than the 56% adherence rate observed in the advanced PCD group.
Position Statement and Future Outlook
The AVF and AVLS position statement, published in the March 2026 issue of JVS-VL, concludes that, given its multimodal approach and patient-friendly design, NPCDs should be considered after conservative treatment failure and included in future guideline assessments. The authors emphasize that NPCDs address limitations of traditional PCDs, enhancing lymphatic and venous return and providing a clinically validated, patient-centric treatment option that improves outcomes and reduces barriers to adherence.
Resources
For more information on venous and lymphatic disease, visit: